Finished reading the first book of 2019.
The book was in the long list of 180 books. The reason to bump it up the queue was a family friend who happens to be a fund manager. While at our place for dinner he browsed the book and kept going back to it. I had ordered the book a week ago, usually, I prefer a Kindle book. As my wife was keen to understand investments and its process, I bought her this book. It landed just a day or two before our friend was to visit us for dinner. To see his keen interest made me prioritise this book over others. And glad I did so — Serendipity at its best. Numerous things had to happen, or else I would have got to this book really late in life.
I am glad I read this. Being a Biotechnology student, I know the fundamental technology that goes into the products. I also know how clinical trials are done, a course I dropped out of but studied enough to understand and remember the clinical trial regime. As Steve Jobs said, the dots connect.
The first section of the book deals about the birth of the industry. Talks about the early startups and the people involved. Having heard about these industry stalwarts it was mesmerising to see the risks these guys took and their persistence to make biotech happen.
The following section talks about the technology itself, genetic engineering, signal transduction etc.. If you are a non-science person, then the technical bit will be of interest and you may also find it a science fiction like.
The third section deals with product development and financing. This was helpful to understand how and where the capital is employed and how collaborations are important in Biotech companies as it takes around a decade to bring a product from a concept to the lab through to the market.
What I learnt is –
With my academic background. the technical understanding and being able to play the long game, Biotech is a favoured industry to invest.
Follow #From Alchemy to IPO tag for interesting snippets.